AgelessRx

AgelessRx Science-backed longevity care, made simple. A portion of every purchase supports longevity research, helping drive the future of age-defying healthcare.

AgelessRx is a first-of-its-kind telehealth platform for longevity, delivering personalized, science-backed care that targets aging at its root. From prescription therapies to ongoing clinical support, our mission is to make expert-guided, preventative care accessible, empowering more people to take control of their healthspan to live healthier, longer lives.

09/08/2026

One of the most persistent assumptions in medicine is that the right drug, at the right dose, can solve a complex problem on its own. Aging has never fit that model, and the research keeps confirming it.

Every biological system involved in how we age, inflammation, mitochondrial function, hormonal signaling, metabolic health, muscle integrity, interacts with the others. Intervening on one without accounting for the rest is a bit like addressing one leak in a dam while the others widen. The effect is real but incomplete, and the window for meaningful impact closes faster than most people realize.

This is the scientific premise behind our entry into the XPRIZE Healthspan competition, one of the most ambitious scientific challenges in the world dedicated to extending the healthy human lifespan. Our semifinals pilot tested whether combining repurposed medications and supplements with structured behavioral therapies produced something greater than the sum of its parts, and the early data was compelling enough to shape the design of our final trial: nine repurposed medications and supplements working alongside progressive resistance training, guided meditation, and health coaching, tested together as a unified protocol rather than a collection of individual interventions.

Being XPRIZE Healthspan Finalists means we are now among a select group of teams worldwide working to answer one of the most important questions in medicine: not just which longevity interventions work, but how they work together at scale. That is the question we are most committed to answering, and we will keep sharing what we learn along the way.

(For educational purposes only)

09/05/2026

During the evaluation process, Dr. Jamie Justice, Executive Vice President of Health at XPRIZE and an adjunct professor of gerontology and geriatric medicine at Wake Forest University School of Medicine, noted something: that AgelessRx is one of the only approaches in the competition that looks like it could roll out to just about anyone, anywhere. Coming from someone who has spent her career studying the biology of aging and now oversees the entire XPRIZE Healthspan effort, that observation means something.

In a field that includes gene therapies, monoclonal antibodies, and some of the most cutting-edge targeted interventions in existence, that's a real distinction. Longevity science has a reach problem. The most exciting interventions being developed today are, in many cases, years away from broad accessibility, and some may never be. What we have built at AgelessRx is a clinician-guided, telehealth-delivered approach to drug repurposing that is already treating real patients, at scale, right now. The judges saw that not as a limitation compared to more targeted therapies, but as a distinct and meaningful advantage worth fighting for.

The goal has always been to make science-backed longevity care accessible to people who would never otherwise have it, not just those who can afford cutting-edge treatments or live near specialized clinics. If the data shows an effect, and we believe it will, the infrastructure to deliver it broadly already exists.

(For educational purposes only)

09/03/2026

For Dr. Robert Dudley, this competition isn't just about the science. It's about what the science makes possible. XPRIZE Healthspan empowers researchers to run studies that go beyond a number on a lab report. The goal: helping patients feel measurably better, with more energy for the years and people that matter most to them.

Helping others has been the throughline of his entire career. This is just the latest chapter.

We're proud to be part of research aimed at real, lived impact, not just data points.

(For educational purposes only)

Muscle loss on GLP-1s gets blamed on the drug. A new mouse study suggests that's not the full story.Obese mice were give...
09/02/2026

Muscle loss on GLP-1s gets blamed on the drug. A new mouse study suggests that's not the full story.

Obese mice were given Semaglutide alone or Semaglutide plus ketone esters for 3 weeks. The Semaglutide-only group lost about 55% of body weight, but also lost roughly 9 grams of muscle, along with signs of muscle atrophy including reduced strength and altered gene expression. The group that also received ketone esters lost less weight overall, about 36%, but lost only around 3 grams of muscle, with no meaningful difference in fat loss between groups. That's roughly 67% less muscle loss for a similar reduction in fat.

This points to something important: the muscle loss often associated with GLP-1s may not be about the medication itself. It may be about how the body handles a steep, unsupported calorie deficit, something that can happen with any rapid weight loss, GLP-1 or not.

A few caveats worth naming. This is a mouse study, and fat metabolism differs meaningfully between mice and humans. The weight loss here was also rapid and extreme, with high daily doses of both Semaglutide and ketone esters, not the gradual titration typically used in practice. This is hypothesis-generating, not conclusive.

What is well established: adequate protein intake and resistance training remain essential tools for preserving muscle during any significant weight loss.

Read the full breakdown. Link in bio.

(For educational purposes only)

Peptides are everywhere right now, but most of the buzz isn't backed by much data.Many trending peptides have little to ...
08/31/2026

Peptides are everywhere right now, but most of the buzz isn't backed by much data.

Many trending peptides have little to no human clinical research behind them. PT-141 is different. It's been studied in humans since the early 2000s, with decades of clinical history and an FDA approval behind it.

That history matters. Years of trials tell a very different story than a trending post, and most of that research predates the current peptide wave entirely. This isn't a new discovery riding a trend. It's an established one getting new attention.

When you're looking at any peptide, the real question isn't how popular it is. It's how much research stands behind it.

See the research behind it. Link in bio.

(For educational purposes only)

08/29/2026

Can a peptide really change how we think about intimacy?

In two major randomized, placebo-controlled clinical trials, women with hypoactive sexual desire disorder took PT-141 and saw measurable changes across multiple validated measures, not just self-reported mood. Desire scores rose significantly on the Female Sexual Function Index, and distress scores dropped significantly on the Female Sexual Distress Scale, both compared to placebo.

Using a responder analysis, a method that defines a clinically meaningful threshold rather than just averaging scores, 58% of women taking PT-141 showed a meaningful improvement in desire, compared to 36% on placebo.

That gap matters. PT-141 doesn't work like most people assume. It acts directly on melanocortin receptors in the brain, specifically MC4R, to influence the neural pathways behind desire and motivation, rather than working on blood flow the way other treatments do.

Learn more about PT-141 at the link in bio.

(For educational purposes only)

08/27/2026

AgelessRx is one of 10 finalist teams selected out of nearly 800 to compete in the XPRIZE Healthspan finals.

This isn't just a competition to us. It's an opportunity to prove that decline isn't the default setting of aging.

For too long, we've watched the people we love fade and assumed that's just what getting older looks like. We don't accept that. XPRIZE Healthspan gives us the platform to run the kind of research that could change what aging actually means, not just adding years to a lifespan, but adding life to those years.

This is what we've been working toward. And we're just getting started.

(For educational purposes only)

Check your biomarkers before something’s wrong. Treat your annual bloodwork like it’s just as important as any other app...
08/25/2026

Check your biomarkers before something’s wrong. Treat your annual bloodwork like it’s just as important as any other appointment on your calendar. Prioritize your health instead of waiting for a wake-up call.

The healthiest people we know aren’t reactive. They’re not waiting for a diagnosis to start paying attention. They’re tracking, testing, and making decisions based on data, not guesswork.

Your longevity plan should be as intentional as everything else in your routine.

(For educational purposes only)

We were featured in NPR this week for something the longevity world has been paying close attention to.The piece explore...
08/24/2026

We were featured in NPR this week for something the longevity world has been paying close attention to.

The piece explores tadalafil, better known as Cialis, and the growing body of research suggesting it may have meaningful benefits well beyond its original indication. An analysis of more than 8,000 men taking tadalafil found a 55% lower rate of dying from cardiovascular causes and a 44% lower rate of overall mortality during the study period. A separate study drawing on more than half a million patients showed a 32% lower risk of dementia among those taking the drug. The findings are observational, and researchers are careful to note that randomized trials are still needed, but the signal across the literature is remarkably consistent.

AgelessRx Medical Director Dr. Jenell Decker was interviewed for the piece, speaking to why the existing data is strong enough to warrant offering low dose tadalafil to both men and women over 40 for longevity purposes. In longevity medicine, waiting for perfect data often means waiting until someone is already behind. The prevention window matters, and acting within it is the entire point.

The Princeton Consensus Panel, an influential group of preventive cardiologists and men’s health experts, recently arrived at consensus language that low dose tadalafil is appropriate for a subset of men at elevated cardiovascular risk, a signal that this conversation is moving beyond wellness circles and into mainstream clinical medicine.

We are proud to be part of a conversation that is pushing longevity science forward in a serious and evidence-informed way.

Read the full NPR article at the link in bio.

(For educational purposes only)

We were featured in NPR this week for something the longevity world has been paying close attention to.The piece explore...
08/24/2026

We were featured in NPR this week for something the longevity world has been paying close attention to.

The piece explores tadalafil, better known as Cialis, and the growing body of research suggesting it may have meaningful benefits well beyond its original indication. An analysis of more than 8,000 men taking tadalafil found a 55% lower rate of dying from cardiovascular causes and a 44% lower rate of overall mortality during the study period. A separate study drawing on more than half a million patients showed a 32% lower risk of dementia among those taking the drug. The findings are observational, and researchers are careful to note that randomized trials are still needed, but the signal across the literature is remarkably consistent.

AgelessRx Medical Director Dr. Jenell Decker was interviewed for the piece, speaking to why the existing data is strong enough to warrant offering low dose tadalafil to both men and women over 40 for longevity purposes. In longevity medicine, waiting for perfect data often means waiting until someone is already behind. The prevention window matters, and acting within it is the entire point.

The Princeton Consensus Panel, an influential group of preventive cardiologists and men's health experts, recently arrived at consensus language that low dose tadalafil is appropriate for a subset of men at elevated cardiovascular risk, a signal that this conversation is moving beyond wellness circles and into mainstream clinical medicine.

We are proud to be part of a conversation that is pushing longevity science forward in a serious and evidence-informed way.

Read the full NPR article at the link in bio.

(For educational purposes only)

Address

Ann Arbor, MI

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Website

Alerts

Be the first to know and let us send you an email when AgelessRx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to AgelessRx:

Shortcuts

Share